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Arachidonic acid (AA) is considered essential in fetal development and some of its metabolites are thought to be important mediators of the
immune responses. Therefore, we studied whether prenatal exposure to AA is associated with some immune-related clinical conditions and
plasma markers in childhood. In 280 children aged 7 years, atopy, lung function and plasma inflammation markers were measured and their
relationships with early AA exposure were studied by linear and logistic regression analyses. AA exposure was deduced from AA concentrations
in plasma phospholipids of the mothers collected at several time points during pregnancy and at delivery, and in umbilical cord plasma and arterial
and venous wall phospholipids. In unadjusted regression analyses, significant positive associations were observed between maternal AA concen-
trations at 16 and 32 weeks of pregnancy (proxies for fetal AA exposure) and peak expiratory flow decline after maximal physical exercise and
plasma fibrinogen concentrations of their children, respectively. However, after correction for relevant covariables, only trends remained. A sig-
nificant negative relationship was observed between AA concentrations in cord plasma (reflecting prenatal AA exposure) and the average daily
amplitude of peak expiratory flow at rest, which lost significance after appropriate adjustment. Because of these few, weak and inconsistent
relationships, a major impact of early-life exposure to AA on atopy, lung function and selected plasma inflammation markers of children at
7 years of age seems unlikely.
Prenatal arachidonic acid: Atopy: Lung function: Plasma inflammation markers
There is increasing evidence that exposure to nutritional
factors, such as n-6 and n-3 PUFA, during the perinatal
period may influence the development of the immune
system and subsequent immune competence(1). The n-6 and
n-3 PUFA are important structural components of cell mem-
branes and particularly arachidonic acid (AA) is prominently
present in immune cell membrane phospholipids (PL)(2,3).
AA may influence the developing immune system because
it is the precursor of PGE2, which is thought to be an
important mediator of immune responses(4,5). During preg-
nancy, the maternal essential fatty acid (EFA) status declines
and because the EFA status of the neonate is strongly corre-
lated with the EFA status of its mother(6), the AA supply to
the developing fetus and its immune system may not always
be optimal.
Previous studies investigated the relationship between the
maternal intake of long-chain n-3 PUFA during pregnancy
and immune-related variables of their offspring(7,8). However,
only a few studies considered the relationship between the pre-
natal long-chain n-6 PUFA status, especially AA, and
immune-related variables, such as atopy later in life. Galli
et al. observed that babies who developed atopic disease
after 1 year of birth had 20–40% lower levels of AA in
their serum cord blood cells in comparison with non-atopic
babies(9). In contrast, Yu et al. found no significant differences
in any of the fatty acid levels, measured in umbilical venous
blood samples, of babies who did or did not develop allergic
diseases during the first 6 years of life(10). Furthermore,
Newson et al. studied the relationship between levels of
various n-3 and n-6 series fatty acids, including AA, in
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erythrocyte PL of women in late pregnancy and in erythrocyte
PL of the umbilical cord of their children, and the prevalence
of wheezing and eczema of the child from birth until 6 months
and from age 30–42 months(11). No significant associations
were observed after adjustment for covariables. Thus, the
relationship between prenatal AA concentrations and later
immune-related variables remains relatively unexplored.
Therefore, we investigated in a mother–child cohort the
associations between the AA levels of maternal plasma PL,
during early, middle and late pregnancy (as proxies for fetal
AA exposure), and several immune-related clinical conditions
and inflammation markers of the child at 7 years of age. In
addition, we also investigated if these immune-related vari-
ables were associated with PL AA concentrations collected
in cord plasma and vessel walls of the newborns, all assumed
to reflect prenatal AA exposure.
Subject and methods
Study population and design
The Maastricht Essential Fatty Acid Birth (MEFAB) cohort
resulted from observational studies performed during 1990–7,
which investigated the associations between maternal or neo-
natal EFA status during pregnancy and pregnancy outcome in
approximately 1200 pregnant women and most of their
infants(12,13). In 1997, the parents of the 750 singleton infants
born between 1990 and 1994 were approached for an extensive
follow-up and eventually 305 children participated in these
studies between 1997 and 2000(14,15). Results of this follow-up
were also entered in the MEFAB database, which provided all
data for the present study. Childrenwith an unknown gestational
age at birth or who were born before 37 weeks gestational age or
after 43 weeks of pregnancy were excluded (n 25). Ultimately,
the data of 280 children and their mothers were available for
the present statistical analysis. Unadjusted and multivariable-
adjusted regression models were applied to explore if maternal
or neonatal AA concentrations, measured during pregnancy
and/or directly after delivery, are related to childhood
immune-related variables.
Blood and tissue sampling and fatty acid measurements
Maternal venous blood samples were collected in EDTA tubes
around the 16th, 22nd and 32ndweek of pregnancy, and immedi-
ately after delivery. Umbilical cord blood and a piece of the
umbilical cord were obtained immediately after parturition.
About 7 years later, after an overnight fast, venous blood from
the children was collected by venepuncture in EDTA-treated
evacuated tubes. Plasma was separated from blood cells by cen-
trifugation. Plasma and umbilical tissue samples were stored
under N2 at 2808C until analysis. The fatty acid composition
of PL isolated from plasma and cord vein and artery walls was
determined by capillary GLC as described elsewhere(6,16).
Fatty acids are expressed as relative values (% by weight of
total identified PL-associated fatty acids).
Explanatory variables
Four explanatory neonatal variables were taken to reflect
prenatal AA exposure, i.e. the relative AA concentrations of
PL isolated from umbilical plasma and from the walls of the
cord vein and artery, and the difference between these latter
two concentrations, which we considered a proxy for fetal
AA consumption(17). The AA concentrations of maternal
plasma PL at approximately 16, 22 and 32 weeks of gestation
and at delivery were applied as four additional explanatory
variables. These variables are taken to reflect the AA status
of the fetus during gestation, since the maternal and neonatal
EFA statuses are strongly correlated(6).
Dependent variables
The following immune-related variables were modelled as
dependent variables in the regression analyses: presence of
atopic clinical conditions, peak expiratory flow (PEF) out-
comes and plasma concentrations of a number of inflammation
markers (all described later).
Atopy assessment. For the atopy assessment of the chil-
dren, parents completed an atopy questionnaire, based on the
Maastricht Atopy List(18) and the well-validated(19,20) Inter-
national Study of Asthma and Allergies in Childhood
(ISAAC) questionnaire(21). This questionnaire included
queries about typical atopy-related symptoms, categorised
per atopic organ(22), such as ‘Has your child ever had allergic
complaints such as eczema, hay fever, and/or food allergy?’,
‘Has your child ever had asthma or asthmatic bronchitis?’
and ‘Has your child ever had wheezing or whistling in the
chest?’. In addition, the following question about allergy
tests was included: ‘Has your child ever undergone an allergy
test like a skin-prick test, radioallergosorbent test (RAST),
elimination test or otherwise? If yes, what was the test
result?’. From these questionnaires, the presence of atopy
was evaluated by a paediatric pulmonologist (J. J. E. H.)
and scored ‘yes’ or ‘no’ when, respectively, more than one
or none of the above-mentioned clinical conditions were con-
clusively manifest. Children whose diagnosis was inconclu-
sive (scoring only one of the above-mentioned clinical
conditions) were excluded from the analysis to prevent bias
introduced by misclassification.
Peak flow measurements. Asthma is a chronic inflamma-
tory disorder of the airways in which many different cell
types play a role. In susceptible individuals this inflammation
causes symptoms which are usually associated with wide-
spread but variable airflow obstruction, that is often reversible
either spontaneously or with treatment, and causes an associ-
ated increase in airway responsiveness to a variety of stim-
uli(23). PEF measurements are often used in everyday
clinical and epidemiological environments for measuring the
severity in airflow obstruction of asthma, to characterise the
clinical trial population and to describe the response to treat-
ment(24). In addition, investigators of previous studies
observed that in children with asthmatic symptoms atopy
was associated with a greater within-day and between-day
variation in PEF(25,26). To assess pulmonary function in the
present study, PEF was measured using a Mini-Wright peak
flow meter. Measurements were carried out at rest (at home)
and before and after maximal physical exercise (at the labora-
tory), both after instructions of the research team. Under the
supervision of the parents, PEF measurements at rest were per-
formed for 2 weeks, five times per d during the morning
(between 07.00 and 09.00 hours) and five times per d during
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the evening (between 19.00 and 21.00 hours). Each day, the
highest PEF value in the morning and the highest value in
the evening were recorded. To increase the reliability of the
measurements, these values were only accepted if at least
two other PEF values (of that series of five measurements)
fell within a range of 10% of that highest value. If this was
not the case, this procedure was repeated with the next highest
PEF value, etc, until two PEF values fell within the 10%
range of that next highest PEF value, otherwise a missing
value was generated. The average highest PEF value at rest
in the morning (PEF morning) was calculated for the
2-week measurement period. In addition, the PEF daily ampli-
tude was calculated as the difference between the highest
morning and highest evening PEF value and expressed as a
percentage of the mean(27). The average daily PEF amplitude
(PEF amplitude) was calculated over the 2-week measurement
period. To measure PEF decline after exercise provocation
(PEF exercise), PEF measurements were performed at the lab-
oratory three times before, and three times at 2, 5, 10 and
15min after reaching maximal exercise with the Bruce tread-
mill test(28,29), of which the highest PEF value was recorded
each time. PEF decline after exercise provocation was calcu-
lated as: ((PEFhighest value before exercise 2 PEFlowest value after
maximal exercise)/PEFhighest value before exercise) £ 100%(30).
Plasma inflammation markers. The following factors are
involved in different processes of the inflammatory response
and were therefore chosen as dependent variables: fibrinogen
(g/l)(31), C-reactive protein (CRP; mg/l)(32), leptin (mg/l)(33)
and von Willebrand factor concentrations(34). In addition,
total leucocyte counts ( £ 109/l blood) were measured, as
well as the absolute and relative amounts of lymphocytes, gra-
nulocytes and monocytes (% of total leucocytes)(35).
Fibrinogen was assayed by the Clauss method(36) and CRP
was measured with an in-house ELISA using polyclonal anti-
bodies as catching and tagging antibodies labelled with horse-
radish peroxidase (DAKO, Glostrup, Denmark). Plasma leptin
concentrations were measured with a commercial human
leptin RIA kit (Linco Research, St Charles, MO, USA) accord-
ing to the manufacturer’s instructions. The relative plasma
content of von Willebrand factor was measured by the
Cejka method(37). The inter-assay and intra-assay CV were
3·3 and 3·6% (fibrinogen), 6·5 and 3·2% (CRP), 8·2 and
6·0% (leptin) and 5·1 and 5·7% (von Willebrand factor).
Total leucocyte counts and relative granulocyte, lymphocyte
and monocyte counts were determined on a Coulter Counter
(Coulterw GEN.S; Beckmann Coulter Inc., Fullerton, CA,
USA) following the manufacturer’s instructions.
Covariables
The following variables were considered potential confoun-
ders: socio-economic status (SES)(38), parity (none, one or
$ two children) at study entry(12,39), maternal smoking
during pregnancy and anyone smoking at home during the
7-year follow-up period (both measured as total number of
cigarettes/1000)(40), breast-feeding (number of months)(41),
maternal age at study entry (years)(42), infant sex(43), gesta-
tional age (weeks)(6,12), parent ethnicity (Caucasian or
not)(43), birth season (divided into quarters)(44), season of
follow-up measurements (divided into quarters)(45), day-care
attendance (total number of days/100)(46), parental history of
atopy (none, one of the parents, or both) assessed at follow-
up(41) and weight gain during the first year of life corrected
for infant sex and age (SD scores)(47). The relative dihomo-g-
linolenic acid, EPA and DHA concentrations in umbilical cord
plasma and vein and artery wall PL, and in maternal plasma
PL, as well as the relative AA concentration of plasma PL of
the children at follow-up were also selected as potential covari-
ables(48). Exact information on SES was not available. There-
fore, parental SES was measured by proxy, using ‘income’ as
an SES indicator, based on the parental postal code at the time
of delivery (Geomarktprofiel; Wegener DM, The Netherlands).
This information was classified in five groups ranging from 1
(twice or more modal income) to 5 (minimum income); SES
values in the categories unknown (0) and diverse (6) were
omitted and, thus, reported as missing values. Children who
never received breast milk were classified as formula-fed and
the remaining children as breast-fed. The following covariables
were considered confounders in the models with PEF-related
outcomes only: endurance time (time required until maximal
exercise was reached, abstracted from the Bruce treadmill
test)(28), site of first PEF measurement (at the laboratory with
extensive instructions by the research team or at home, with
written instructions only) and children’s height and weight at
follow-up (age 7 years)(49).
Data evaluation and statistical analysis
All data are presented as medians and interquartile ranges,
unless otherwise mentioned. Unadjusted and multivariable-
adjusted linear and logistic regressions were performed to
test the associations between maternal and neonatal AA
concentrations and the immune-related variables. Before
this, data distributions of the dependent variables were
checked by means of the Shapiro–Wilk test; in case of skew-
ness transformation was applied (natural log, square root,
square or 1/square) to optimise the data distribution towards
normal. When transformation improved but did not normalise
the distribution, linear regression analyses were still
performed, but results were accepted only if the residuals
were normally distributed. If this was not the case, the vari-
ables were dichotomised and logistic regression analyses
were performed. In the regression analyses with maternal
AA levels this appeared the case for absolute monocyte
counts and leptin concentrations. Therefore, these variables
were analysed as dichotomous variables ($median v.
,median). The same was done for fibrinogen and leptin con-
centrations in relation to neonatal AA concentrations. The von
Willebrand factor values were biphasically distributed with
the point of overlap situated at 68%. Therefore, this variable
was analysed as a dichotomous variable also ($68 v. ,68%).
Because the PEF exercise variable had a non-parametric distri-
bution, this variable was also dichotomised. Children without
an asthmatic condition usually have a smaller PEF decline
(,15%) after exercise(23), because they will develop less
bronchoconstriction compared with their asthmatic counter-
parts. Therefore, this value was selected as the threshold for
dichotomisation ($15 v. ,15%).
Values of normally distributed variables (either before or after
transformation) were considered outliers and removed from the
dataset if they were more than four standard deviations away
from the mean. Values of not normally distributed variables,
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even after optimal transformation, were considered outliers and
were removed from the dataset if their values were more than
three interquartile ranges below or above the median.
Insufficient complete cases were available to allow
inclusion of all the above-mentioned covariables in the ana-
lyses. Therefore, for each of the fifteen dependent variables
and each covariable, bivariable regression analyses were per-
formed which included one dependent variable, one explana-
tory variable and one covariable. These analyses were used
to determine which of the covariables contributed to the
relationships between dependent and explanatory variables,
either as a significant predictor (P,0·05) or as a confounder
(if its removal caused the B-value to change at least
10%, and 20% or more of the standard error of this
B-value)(50). Only covariables that appeared predictors or con-
founders were included in the various multivariable-adjusted
analyses. For practical reasons, bivariable analyses were
only done for AA concentrations in maternal plasma PL at
32 weeks of gestation and for AA concentrations in cord
artery wall PL. The selected covariables were subsequently
included in all models with corresponding maternal or
neonatal AA variables. For all unadjusted and multivariable-
adjusted regression analyses the same complete dataset was
used. Data points suspected of being overly influential were
checked by calculation of their Cook’s distances and removed
if their values were .1. Such influential data points were
observed in four multivariable-adjusted regression models,
but exclusion of these data points did not alter the final results.
Atopy and the three pulmonary function variables were
regarded as the dependent variables of primary interest.
Relationship studies with these variables were, therefore, con-
sidered the primary analyses. All other relationships were
regarded of secondary interest. The significance level for the
primary analyses was set at a threshold of P,0·05, with
P,0·10 indicating a non-significant trend. Secondary relation-
ships were considered significant at P,0·01, to correct for
multiple comparisons, and P,0·05 indicated a non-significant
trend.
SPSS 11.5 for Windows (SPSS, Inc., Chicago, IL, USA)
was used for all statistical analyses.
Results
An overview of the relative concentrations of the maternal and
neonatal fatty acids of interest is given in Table 1. The
immune-related parameters of the children measured at
7 years of age are presented in Table 2. The maternal and neo-
natal characteristics screened as covariables are shown in
Tables 3 and 4. In Tables 5 and 6, results of the regression
analyses are only shown for combinations of dependent and
explanatory variables with significant or trend contributions
of AA to either the unadjusted or multivariable-adjusted
models. Full results are available on request.
Associations between maternal arachidonic acid status and
childhood immune-related clinical parameters
A negative trend was observed for the unadjusted association
between the natural log-transformed PEF amplitude and
maternal AA levels at the 22nd week of pregnancy
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in the multivariable-adjusted analysis (Table 5). A significant
positive association and a positive trend were observed for the
unadjusted relationships between PEF exercise values and the
AA levels in maternal plasma at 16 weeks of pregnancy
(P¼0·033) and directly after delivery (P¼0·097), respecti-
vely. In these unadjusted models, differences in AA concen-
trations explained 4·5 and 2·8% of the variance in PEF
exercise, respectively. After adjustment of both models for rel-
evant covariables, only a positive trend remained for the first
relationship (P¼0·059), in which AA explained 3·5% of the
variation in PEF exercise.
For all other combinations of maternal AA concentrations
and immune-related clinical parameters no significant associ-
ations or trends were found.
Associations between the maternal arachidonic acid status
and childhood immune-related plasma variables
The only significant relationship observed in the unadjusted
analyses was a positive association between the AA levels
at week 32 of pregnancy and fibrinogen concentrations in
children’s plasma at follow-up (linear regression analysis
after quadratic transformation of fibrinogen concentrations;
P¼0·006) (Table 5). After adjustment for the child’s AA
concentration at follow-up, the association lost significance
(P¼0·014, which is higher than 0·01 that was set for the
secondary analyses) and differences in maternal AA concen-
trations explained 2·9% of the variance in fibrinogen levels.
Negative trends were observed for the unadjusted associ-
ations of the relative and absolute monocyte counts with
AA concentrations at the 16th week of pregnancy. The
models explained 2·1 and 4·5% of the variance in relative
(P¼0·030) and absolute (P¼0·034) monocyte counts,
respectively. These trends persisted after adjustment for
the appropriate covariables, which resulted in models in
which the AA concentrations explained 1·8% (relative
monocyte values; P¼0·039) and 4·4% (absolute monocyte
counts; P¼0·030) of the monocyte variance. All other
regression analyses revealed no significant associations or
trends.
Table 2. Immune-related variables measured in children at follow-up at age 7 years
(Medians and 25th and 75th percentiles)
Variable n % Median* 25th and 75th percentiles
Atopy
No 183 65·4 N/A
Uncertain 45 16·1 N/A
Yes 52 18·6 N/A
PEF morning (litres/min) 257 214·58 193·96, 242·50
PEF amplitude (%) 255 7·89 5·80, 10·28
PEF exercise (%) 257 5·26 0·00, 10·53
Leucocytes ( £ 109/l) 243 6·60 5·80, 7·70
Monocytes ( £ 109/l) 243 0·40 0·30, 0·50
Granulocytes ( £ 109/l) 245 3·60 2·80, 4·60
Lymphocytes ( £ 109/l) 246 2·50 2·10, 3·00
Monocytes (%) 245 6·20 4·65, 8·00
Granulocytes (%) 244 53·95 47·83, 62·50
Lymphocytes (%) 246 38·95 32·00, 44·43
CRP (mg/l) 232 0·19 0·07, 0·58
Leptin (mg/l) 245 2·85 2·07, 3·93
Fibrinogen (g/l) 233 2·60 2·40, 2·80
vWF (%) 233 81·00 71·00, 84·00
N/A, not applicable; PEF, peak expiratory flow; PEF morning, average PEF in the morning; PEF
amplitude, average PEF daily amplitude; PEF exercise, PEF decline after exercise provocation; CRP,
C-reactive protein; vWF, von Willebrand factor.
* For all variables non-transformed values are given.
Table 3. Maternal and child characteristics used as continuous covariables
(Medians and 25th and 75th percentiles)
Characteristics n Median 25th and 75th percentiles
Maternal age at study entry (years) 280 29·5 26·9, 32·4
Gestational age at birth (weeks) 280 40·1 39·3, 41·0
Infant weight gain during first year of life (SD) 247 1·0 0·3, 1·7
Height at 7-year follow-up (cm) 275 127·0 123·2, 130·4
Weight at 7-year follow-up (kg) 275 24·5 22·2, 27·6
Day-care attendance during 7-year follow-up (total days/100) 272 0·08 0·08, 0·12
Breast-feeding (months) 278 0·00 0·00, 3·00
Maternal smoking during pregnancy (total cigarettes/1000) 280 0·00 0·00, 0·54
Anyone smoking at home during 7-year follow-up (total cigarettes/1000) 276 5·29 0·00, 25·6
Endurance time at 7-year follow-up (min)* 248 10·5 10·0, 11·2
* Time required to reach maximal exercise, calculated from the Bruce test results(28) and considered a measure of physical fitness.
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Associations between neonatal arachidonic acid status and
childhood immune-related clinical parameters
Unadjusted regression analysis showed a significant negative
association between natural log-transformed PEF amplitude
values and AA concentrations in neonatal plasma PL
(R 2 0·026; P¼0·020) (Table 6). However, after adjustment
for relevant covariables, this association was reduced and
no longer significant. A positive trend was observed for the
unadjusted relationship between PEF exercise and the differ-
ence in AA concentrations between the walls of cord arteries
and cord vein (P¼0·087), which explained 4·6% of the vari-
ance in PEF exercise. This positive trend disappeared,
however, after adjustment for the appropriate covariables. No
significant associations or trends were observed for the other
combinations of neonatal AA concentrations and clinical
immune-related variables.
Associations between neonatal arachidonic acid status and
childhood immune-related plasma variables
In unadjusted regression analyses, only a positive trend was
observed for the relationship between absolute lymphocyte
counts (square root-transformed) of the children at follow
up, and their plasma PL AA concentrations at birth
(R 2 0·018; P¼0·038), but this trend did not survive after
adjustment for dihomo-g-linolenic acid and DHA
concentrations in neonatal plasma PL (Table 6). In multivari-
able-adjusted analyses, a negative trend was found for the
relationship between the natural log-transformed plasma
CRP levels of the children at follow-up and the AA concen-
trations measured in the PL of their cord artery walls
(P¼0·019). In this model, AA explained 3·7% of the CRP
variance. A positive trend (P¼0·049) was observed for the
multivariable-adjusted relationship between children’s natural
log-transformed absolute leucocyte counts at age 7 years and
the AA levels of their cord vein wall PL. In this relationship,
AA explained 2·3% of the variance in leucocyte count. No
other important associations or trends were noted (Table 6).
Discussion
In the unadjusted primary analyses of this prospective
mother–child cohort, negative associations were observed
between the average PEF daily amplitude (PEF amplitude)
of 7-year-old children and the AA concentrations in plasma
PL of their mothers at 22 weeks of gestation (reflecting fetal
exposure to AA) and in umbilical plasma PL (reflecting prena-
tal AA exposure). On the other hand, positive associations
were observed between the PEF decline after maximal
exercise (PEF exercise) and maternal AA concentrations at
16 weeks of pregnancy and directly after delivery, respect-
ively. These positive associations are in concordance with
the positive non-significant trend between PEF exercise and
neonatal vein–artery AA differences, which we consider a
proxy of fetal AA consumption. For these associations and
trends, variations in AA levels explained no more than 0·8
to 3·5% of the variability of these immune-associated vari-
ables, strongly suggesting that the prenatal AA status of an
individual hardly contributes to these immune-related aspects
at 7 years of age. This is also supported by the finding that the
associations are not only functionally inconsistent but con-
trasting as well. Since values for PEF amplitude and/or PEF
exercise are usually increased in subjects with an asthmatic
condition(23), the negative associations we observed with
AA exposure imply a beneficial effect of AA on lung function,
if relationships are causal. In contrast, the positive relation-
ships between AA exposure and PEF exercise indicate




Parents’ SES grade (income)
High (1) 4 1·4
Above modal (2) 23 8·2
Modal (3) 44 15·7
Below modal (4) 74 26·4

















Caucasian (0) 270 97·1





Male (0) 152 54·3

















Site of first PEF measurement
At laboratory (0) 106 37·9
At home (1) 152 54·3
Missing 22 7·9
Total 280 100
SES, socio-economic status; PEF, peak expiratory flow.
* 1 ¼ January–March, 2 ¼ April–June, 3 ¼ July–September, 4 ¼ October–
December.
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Table 5. Unadjusted and multivariable-adjusted linear (LIN) and logistic (LOG) regression analyses of the relationships between plasma phospholipid (PL) arachidonic acid (AA) concentrations of
mothers sampled during pregnancy and at delivery, and immune-related variables measured in their children at 7 years of age
Unadjusted analysis results Multivariable-adjusted analysis results†
Pregnancy week
Dependent




LIN 207 0·016 20·04 20·13 0·069 20·09, 0·00 0·040 20·03§ 20·09 0·008 0·204 20·08, 0·02
16 PEF exercise
($15 % decline)
LOG 212 0·045 0·34 1·40 0·033* 1·03, 1·90 0·077 0·33k 1·38 0·035 0·059 0·99, 1·94
Delivery PEF exercise
($15 % decline)




LIN 208 0·036 0·28 0·19 0·006* 0·08, 0·47 0·044 0·25†† 0·17 0·029 0·014 0·05, 0·45
16 Monocytes (%) LIN 225 0·021 20·24 20·14 0·030 20·45, 20·02 0·077 20·22‡‡ 20·13 0·018 0·039 20·43, 20·01
16 Monocytes
($0·40 £ 109/l)
LOG 139 0·045 20·27 0·77 0·034 0·60, 0·98 0·155 20·30§§ 0·74 0·044 0·030 0·56, 0·97
R 2, coefficient of determination for linear regression, Nagelkerke R square for logistic regression; B, unstandardised regression coefficient; b, the standardised regression coefficient of B for linear regression (LIN), which is the number
of outcome standard deviations that the outcome will change as a result of one predictor standard deviation change in the predictor; OR, OR for logistic regression (LOG); P, P value of AA contribution; 95 % CI, CI of B for linear
regression and of OR for logistic regression, both set at 95 %; r 2, square of the semi-partial correlation coefficient of AA; PEF, peak expiratory flow.
* Significant relationship (P,0·05 for primary analyses; P,0·01 for explorative analyses). A non-significant trend was indicated as 0·05 # P,0·10 for primary analyses and as 0·01 # P,0·05 for secondary analyses.
† The total model P values of the (final) multivariable-adjusted analyses were between 0·000 and 0·178.
‡ Natural log transformation.
§ Covariables: site of first PEF measurement and maternal plasma PL DHA concentrations.
kCovariables: DHA concentrations in maternal plasma PL and AA concentration in children’s plasma PL at follow-up.
†† Covariable: AA concentration in children’s plasma PL at follow-up.
‡‡ Covariable: infant sex.
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Table 6. Unadjusted and multivariable-adjusted linear (LIN) and logistic (LOG) regression analyses of the relationships between phospholipid (PL) arachidonic acid (AA) concentrations in several
umbilical domains of neonates, and their immune-related variables measured at 7 years of age
Unadjusted analysis results Multivariable-adjusted analysis results†









LOG 143 0·046 0·26 1·30 0·087 0·96, 1·76 0·130 0·18k 1·19 0·010 0·396 0·79, 1·79
Secondary analyses
Plasma Lymphocytes
( £ 109/l, square
root{)
LIN 246 0·018 0·02 0·13 0·038 0·00, 0·03 0·028 0·02†† 0·12 0·011 0·105 20·00, 0·03
Artery wall CRP (mg/l, ln‡) LIN 137 0·020 20·10 20·14 0·101 20·21, 0·02 0·153 20·19‡‡ 20·28 0·037 0·019 20·35, 20·03
Vein wall Leucocytes
( £ 109/l, ln‡)
LIN 162 0·023 0·02 0·15 0·054 0·00, 0·04 0·107 0·02§§ 0·17 0·023 0·049 0·00, 0·04
R 2, coefficient of determination for linear regression, Nagelkerke R square for logistic regression; B, unstandardised regression coefficient; b, the standardised regression coefficient of B for linear regression (LIN), which is the number
of outcome standard deviations that the outcome will change as a result of one predictor standard deviation change in the predictor; OR, OR for logistic regression (LOG); P, P value of AA contribution; 95 % CI, CI of B for linear
regression and of OR for logistic regression, both set at 95 %; r 2, square of the semi-partial correlation coefficient of AA; PEF, peak expiratory flow; CRP, C-reactive protein; DGLA, dihomo-g-linolenic acid.
* Significant relationship (P,0·05 for primary analyses). A non-significant trend was indicated as 0·05 # P,0·10 for primary analyses and as 0·01 # P,0·05 for secondary analyses.
† The total model P values of the (final) multivariable-adjusted analyses were between 0·006 and 0·093.
‡ Natural log transformation.
§ Covariables: site of first PEF measurement, maternal age, DGLA and DHA concentrations in neonatal plasma PL, endurance time, parity and infant sex.
kCovariables: umbilical vein–artery differences of DGLA and DHA concentrations, first year weight gain, height at follow-up.
{Square root transformation.
†† Covariables: DGLA and DHA concentrations in neonatal plasma PL.
‡‡ Covariables: parity, maternal smoking during pregnancy, anyone smoking at home during follow-up period, first year weight gain, DGLA and DHA concentrations in umbilical artery wall PL and AA concentration in plasma PL of
children at follow-up.
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a potentially adverse effect of AA. Finally, in the multivari-
able-adjusted analyses most significant results and trends
disappeared.
Concerning the secondary analyses with the immune-related
plasma markers, one significant positive association was
shown between maternal AA concentrations at 32 weeks of
pregnancy and plasma fibrinogen concentrations of the children
at 7 years of age. For some other associations only trends were
revealed but, like the primary analyses, no more than about
4% of the functional variability was explained by differences
in AA concentration. Moreover, observed associations and
trends were functionally inconsistent again and therefore a
major influence of early AA exposure on these immune-related
plasma markers at age 7 years seems unlikely.
Relationships between early-life exposure to n-3 and n-6
fatty acids and immune-related clinical conditions measured
during childhood have been previously studied(51–54). How-
ever, as far as we know, only a few studies investigated the
associations between prenatal n-6 fatty acid exposure and vari-
ous indicators of immune function in childhood. Newson et al.
did not report any significant association between relative AA
concentrations in erythrocyte PL of umbilical cord blood and
maternal blood collected in a period between 20 weeks of
pregnancy and delivery and the prevalence of wheezing or
eczema up to 42 months of age after adjustment for confoun-
ders(11). Furthermore, Yu et al. also observed no difference in
the relative AA levels of umbilical cord blood PL of children
who did or did not develop allergic disease during the first
6 years of life(10). Both findings are in line with our obser-
vation that plasma AA concentrations before and around
birth are not strongly associated with atopic disease in later
childhood. Since these previously mentioned studies used
shorter periods between fatty acid exposure measurements
and assessment of immune-related variables, it can probably
be excluded that the interval period of 7 years in the present
study was too long to explain the non-significant results.
Galli et al. selected fifty-seven neonates at high risk for
developing atopy and reported that all thirteen newborns
who developed atopic disease during the first 12 months of
follow-up had significantly (20–40%) lower AA levels in
their cord blood PL at birth as compared with their non-
atopic counterparts(9). However, no correction was made for
potential confounders which may have biased their results.
In addition, Sausenthaler et al. suggested that intake of n-6
fatty acid-rich foods, such as margarines and vegetable oils,
during the last 4 weeks of pregnancy was associated with an
increased risk of allergic diseases in children at the age of
2 years(8). Although these foods contain a high content of lino-
leic acid, the increased risk could also be related to one of the
many other components of these products. Furthermore, it is
known from a previous study that a higher maternal intake
of linoleic acid does not relate to higher AA concentrations
in maternal and umbilical plasma PL(55).
A strong aspect of the present study is that maternal and
neonatal fatty acid concentrations were obtained repeatedly
during pregnancy and at parturition, respectively. Since
maternal and neonatal long-chain PUFA concentrations are
strongly correlated(12), this enabled us to investigate the
associations between the child’s immune-related variables at
age 7 years and the AA exposure from the second trimester
of pregnancy on.
Although we tested all relevant variables included in the
database for their confounding or predicting potentials,
residual confounding cannot be excluded, which is a general
shortcoming of observational studies. Due to the absence of
relevant data, we were unable to correct our analyses for
differences in the postnatal AA consumption of the children,
which may have contributed to the inter-individual differences
in immune outcome variables at age 7 years. However, we did
correct for the plasma PL AA concentration at age 7 years,
which can be considered a proxy for the postnatal AA
intake, since there is a positive relationship between dietary
AA intake and plasma PL AA concentration(56,57).
The use of a parent questionnaire to assess the atopic state
of the children is clearly inferior to a full clinical evaluation.
However, in large-scale observational studies, questionnaires
are often the only practical option to gather clinical infor-
mation. It should be added that the questionnaire that we
used was based on the ISAAC questionnaire(21), which has
been properly validated(19,20), showing sensitivity and speci-
ficity of at least 77 and 81%, respectively. Furthermore, as
mentioned before, all questionnaires were ‘scored’ by an
experienced clinician (J. J. E. H.). Therefore, although not
optimal, we consider our atopy-assessment method adequate
for the present observational study. Finally, we cannot exclude
response bias in this cohort study, since informed consent for
the 7-year follow-up was obtained for only 300 out of the
750 eligible mother–child pairs.
In the present study, no clear associations were observed
between atopy at age 7 years and prenatal AA exposure as
reflected by maternal AA concentrations during pregnancy
and at delivery and neonatal AA values at birth. In theory,
this may result from too-narrow ranges in AA concentrations
and/or a too-low atopy incidence in our study population in
relation to our sample size. However, the AA concentrations
measured in our study population compare very well with
maternal(58,59) and neonatal(59,60) values observed in other
studies, whereas the atopy incidence in our population is rela-
tively high as compared with the atopy prevalence reported in
a worldwide study(61). Since the OR for the atopy risk as a
function of the AA concentrations in the various domains
are all close to 1 (0·79–1·11 for the eight domains studied)
and their 95% CI are rather tight around 1 (the widest interval
being 0·66, 1·33), we consider the power of the present study
sufficient for a reliable conclusion. Comparable conclusions
can be drawn for most other immune-associated variables.
This supports the absence of relevant associations between
the perinatal AA availability and selected aspects of the
immune status at the age of 7 years.
In the present study, the same cases were used in the unad-
justed as well as the multivariable-adjusted regression models,
enabling us to check whether confounding was present and in
which direction confounding influenced the model. In general,
results were comparable when unadjusted regression analyses
were performed with the maximum number of cases available
(data not shown).
Finally, in the present study outliers were removed before
statistical analyses were applied. Usually an outlier should
only be omitted from the statistical analyses if there is a bio-
logical explanation as to why this value is inappropriate.
Repeating the statistical analyses with the outliers included
did not fundamentally alter the results: non-significant results
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did not become significant and vice versa. So, the final results
and the conclusions of the present study did not change when
the outliers were added in the analyses.
In conclusion, we investigated whether normally occurring
differences in prenatal AA availability could be of importance
for the later presence of atopy, lung function and plasma
inflammation markers. From the results obtained, such
an influence seems rather unlikely since physiological differ-
ences in prenatal exposure to AA show few, weak and incon-
sistent associations with differences in several immune-related
clinical conditions and plasma markers at 7 years of age. Gen-
etic predisposition and in utero exposure to other factors are
possibly more important determinants of these variables than
prenatal AA concentrations. However, because of the limi-
tations of the present observational study (mentioned above),
the involvement of early AA status in the development of
the immunological system cannot be excluded.
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